AUD 0.0
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 | -3.49 Million AUD | 64.33% |
2023 | -9.78 Million AUD | 13.36% |
2022 | -11.52 Million AUD | -94.96% |
2021 | -5.68 Million AUD | -68.6% |
2020 | -3.32 Million AUD | -2.47% |
2019 | -3.36 Million AUD | -37.3% |
2018 | -2.9 Million AUD | -5.93% |
2017 | -1.42 Million AUD | -35.87% |
2016 | -1.56 Million AUD | -386.93% |
2015 | -2.88 Million AUD | 95.65% |
2014 | -7.31 Million AUD | -71.24% |
2013 | -4.69 Million AUD | 23.84% |
2012 | -6.16 Million AUD | 0.15% |
2011 | -6.39 Million AUD | 3.9% |
2010 | -6.42 Million AUD | 19.47% |
2009 | -7.94 Million AUD | -9.33% |
2008 | -6.93 Million AUD | 0.0% |
2007 | - AUD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -1.92 Million AUD | 0.0% |
2024 FY | - AUD | 50.34% |
2024 Q4 | -1.56 Million AUD | 0.0% |
2023 Q2 | -3.86 Million AUD | 0.0% |
2023 Q4 | -3.14 Million AUD | 0.0% |
2023 FY | - AUD | 13.36% |
2022 Q2 | -4.48 Million AUD | 0.0% |
2022 Q4 | -2.24 Million AUD | 0.0% |
2022 FY | - AUD | -94.96% |
2021 Q4 | -2.03 Million AUD | 0.0% |
2021 Q2 | -1.98 Million AUD | 0.0% |
2021 FY | - AUD | -68.6% |
2020 FY | - AUD | -2.47% |
2020 Q4 | -1.01 Million AUD | 0.0% |
2020 Q2 | -1.68 Million AUD | 0.0% |
2019 Q2 | -2.08 Million AUD | 0.0% |
2019 FY | - AUD | -37.3% |
2019 Q4 | -1.27 Million AUD | 0.0% |
2018 Q4 | -1.48 Million AUD | 0.0% |
2018 Q2 | -969.38 Thousand AUD | 0.0% |
2018 FY | - AUD | -5.93% |
2017 Q2 | -499.62 Thousand AUD | 0.0% |
2017 FY | - AUD | -35.87% |
2017 Q4 | -487.73 Thousand AUD | 0.0% |
2016 Q2 | -374.43 Thousand AUD | 0.0% |
2016 FY | - AUD | -386.93% |
2016 Q4 | -664.18 Thousand AUD | 0.0% |
2015 FY | - AUD | 95.65% |
2015 Q4 | -458.87 Thousand AUD | 0.0% |
2015 Q2 | -2.42 Million AUD | 0.0% |
2014 Q4 | -3.75 Million AUD | 0.0% |
2014 Q2 | -2.98 Million AUD | 0.0% |
2014 FY | - AUD | -71.24% |
2013 Q3 | -880.65 Thousand AUD | -0.04% |
2013 Q2 | -880.34 Thousand AUD | 30.93% |
2013 FY | - AUD | 23.84% |
2013 Q1 | -1.27 Million AUD | 0.0% |
2013 Q4 | -2.19 Million AUD | -148.72% |
2012 Q1 | -1.79 Million AUD | 0.0% |
2012 Q4 | -1.27 Million AUD | 0.0% |
2012 FY | - AUD | 0.15% |
2012 Q2 | -1.27 Million AUD | 29.03% |
2012 Q3 | -1.27 Million AUD | 0.0% |
2011 Q4 | -1.79 Million AUD | 0.0% |
2011 Q1 | -1.87 Million AUD | 0.0% |
2011 Q2 | -1.79 Million AUD | 4.36% |
2011 Q3 | -1.79 Million AUD | 0.0% |
2011 FY | - AUD | 3.9% |
2010 Q3 | -1.87 Million AUD | 0.0% |
2010 FY | - AUD | 19.47% |
2010 Q1 | -2.15 Million AUD | 0.0% |
2010 Q2 | -1.87 Million AUD | 13.03% |
2010 Q4 | -1.87 Million AUD | 0.0% |
2009 Q1 | -1.82 Million AUD | 0.0% |
2009 FY | - AUD | -9.33% |
2009 Q4 | -2.15 Million AUD | 0.0% |
2009 Q2 | -2.15 Million AUD | -18.34% |
2009 Q3 | -2.15 Million AUD | 0.0% |
2008 FY | - AUD | 0.0% |
2008 Q1 | - AUD | 0.0% |
2008 Q3 | -1.82 Million AUD | 0.0% |
2008 Q2 | -1.82 Million AUD | 0.0% |
2008 Q4 | -1.82 Million AUD | 0.0% |
2007 FY | - AUD | 0.0% |
2007 Q4 | - AUD | 0.0% |
2007 Q3 | - AUD | 0.0% |
2007 Q2 | - AUD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
EZZ Life Science Holdings Limited | 10.37 Million AUD | 133.658% |
Anatara Lifesciences Ltd | -1.45 Million AUD | -139.736% |
Zelira Therapeutics Limited | -36.44 Million AUD | 90.417% |
Biome Australia Limited | -1.57 Million AUD | -121.267% |
Orthocell Limited | -11.68 Million AUD | 70.104% |
Imugene Limited | -147.97 Million AUD | 97.64% |
Noxopharm Limited | -5.94 Million AUD | 41.264% |
PYC Therapeutics Limited | -38.11 Million AUD | 90.838% |
Chimeric Therapeutics Limited | -11.29 Million AUD | 69.095% |
Prescient Therapeutics Limited | -7.18 Million AUD | 51.401% |
Proteomics International Laboratories Limited | -7.88 Million AUD | 55.724% |
Cynata Therapeutics Limited | -9.95 Million AUD | 64.904% |
CSL Limited | 4.73 Billion AUD | 100.074% |
Arovella Therapeutics Limited | -8.83 Million AUD | 60.465% |
Bio-Gene Technology Limited | -2.97 Million AUD | -17.384% |
Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 106.733% |
Starpharma Holdings Limited | -12.57 Million AUD | 72.234% |
Nanollose Limited | -1.14 Million AUD | -204.221% |
Memphasys Limited | -3.3 Million AUD | -5.576% |
Invex Therapeutics Ltd | -720.44 Thousand AUD | -384.724% |
NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -94.41% |
Amplia Therapeutics Limited | -4.55 Million AUD | 23.411% |
Botanix Pharmaceuticals Limited | -13.91 Million AUD | 74.912% |
Island Pharmaceuticals Limited | -2.81 Million AUD | -23.918% |
Race Oncology Limited | -14.2 Million AUD | 75.413% |
Nyrada Inc. | -4.59 Million AUD | 24.021% |
Telix Pharmaceuticals Limited | 22.96 Million AUD | 115.206% |
Dimerix Limited | -24.95 Million AUD | 86.008% |
PharmAust Limited | -9.45 Million AUD | 63.053% |
Immutep Limited | -42.87 Million AUD | 91.855% |
Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 92.178% |
Alterity Therapeutics Limited | -19.57 Million AUD | 82.157% |
BTC Health Limited | 1.05 Million AUD | 430.92% |
Acrux Limited | -7.93 Million AUD | 55.968% |
Neuren Pharmaceuticals Limited | 199.26 Million AUD | 101.753% |
Biotron Limited | -5.04 Million AUD | 30.712% |
Tissue Repair Ltd | -5.77 Million AUD | 39.53% |
AdAlta Limited | -5.3 Million AUD | 34.144% |
Radiopharm Theranostics Limited | -45.37 Million AUD | 92.304% |
Hexima Limited | -995.54 Thousand AUD | -250.779% |
AnteoTech Limited | -11.57 Million AUD | 69.82% |
Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 94.589% |
Recce Pharmaceuticals Ltd | -21.35 Million AUD | 83.646% |
Avecho Biotechnology Limited | -3.24 Million AUD | -7.699% |
Actinogen Medical Limited | -12.92 Million AUD | 72.973% |
Immuron Limited | -6.19 Million AUD | 43.605% |
Argenica Therapeutics Limited | -1.89 Million AUD | -84.031% |